• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up.

作者信息

Molica S, Levato D, Levato L

机构信息

Divisione di Ematologia, Ospedale Regionale A. Pugliese Catanzaro, Italy.

出版信息

Haematologica. 1993 Nov-Dec;78(6):374-7.

PMID:8175032
Abstract

BACKGROUND AND METHODS

Infections represent the major cause of death in chronic lymphocytic leukemia (CLL); however, clinical studies dealing with their incidence have yielded inconclusive results. In order to address this issue we reviewed the records of 125 CLL patients (mean age 65.6 yrs; 81 M/44 F; Stage A, 48; Stage B, 37; Stage C, 40) followed up at our institution over a 10-year period.

RESULTS

The 125 patients accrued 447 person-years, a mean of 3.8 years per person. There were 199 recorded infections: 47 severe (crude rate 9.8 per 100 person-years) and 72 moderate, respectively. The 5-year risk of developing a severe infection for the whole series was 26% (95% CI: 24.7-27.3%), and 21 out of 71 deaths (29.5%) could be attributed to infectious causes. Despite a linear trend toward increased risk (r = 0.98), hazard function analysis showed a constant pattern of risk (r = 0.30), suggesting a lack of correlation of this event with time. Furthermore, the 5-year risk of developing a severe infection increased to 57.1% (95% CI: 36.4-77.8%) for patients with low IgG levels (less than 6.5 gr/L), and to 68% for those with both low IgG levels and disease stage C. On the other hand, patients who experienced a severe infection more frequently had advanced clinical stage (P < 0.001), low IgG levels (P < 0.01) and diffuse bone marrow (BM) histology (P < 0.05).

CONCLUSIONS

Infection is a constant risk in CLL that is associated with shortened survival. Factors such as hypogammaglobulinemia and advanced disease appear to be the major predisposing factors.

摘要

相似文献

1
Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up.
Haematologica. 1993 Nov-Dec;78(6):374-7.
2
Clinical and prognostic evaluation of bone marrow infiltration (biopsy versus aspirate) in early chronic lymphocytic leukemia. A single center study.早期慢性淋巴细胞白血病骨髓浸润的临床及预后评估(活检与穿刺抽吸对比):一项单中心研究
Haematologica. 1997 May-Jun;82(3):286-90.
3
Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease-progression on overall survival.早期慢性淋巴细胞白血病的自然病史。一项单机构研究,重点关注疾病进展对总生存期的影响。
Haematologica. 1999 Dec;84(12):1094-9.
4
[Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].[慢性淋巴细胞增殖性疾病白血病类型的临床和实验室预后参数]
Acta Med Croatica. 2008 Oct;62(4):351-64.
5
Second neoplasms in chronic lymphocytic leukemia: analysis of incidence as a function of the length of follow-up.
Haematologica. 1989 Sep-Oct;74(5):481-5.
6
Prognostic value of bone marrow histology in chronic lymphocytic leukemia. A study of 335 untreated cases from a single institution.慢性淋巴细胞白血病中骨髓组织学的预后价值。对来自单一机构的335例未经治疗病例的研究。
Haematologica. 1994 Jul-Aug;79(4):334-41.
7
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.氟达拉滨难治性B细胞慢性淋巴细胞白血病和小淋巴细胞淋巴瘤中严重感染的频率和类型:对该患者群体临床试验的影响
Cancer. 2002 Apr 1;94(7):2033-9.
8
What is changing in the natural history of chronic lymphocytic leukemia?慢性淋巴细胞白血病的自然病程正在发生哪些变化?
Haematologica. 2001 Jan;86(1):8-12.
9
Expression of thrombospondin receptor (CD36) in B-cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination.血小板反应蛋白受体(CD36)在B细胞慢性淋巴细胞白血病中的表达作为肿瘤细胞播散的指标
Haematologica. 1999 May;84(5):419-24.
10
Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.霍奇金淋巴瘤的长期生存:死亡率、第二肿瘤、感染及心血管疾病的相对影响
Cancer J Sci Am. 1995 May-Jun;1(1):33-42.

引用本文的文献

1
Assessment of immunological and hematological parameters in Blastocystis species-infected chronic leukemic patients.对感染芽囊原虫的慢性白血病患者的免疫学和血液学参数评估。
Gut Pathog. 2025 Aug 11;17(1):58. doi: 10.1186/s13099-025-00733-0.
2
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence.CLL 或 NHL 患者的 IgG 检测、免疫球蛋白替代疗法和感染结局:真实世界证据。
Blood Adv. 2024 Aug 27;8(16):4239-4249. doi: 10.1182/bloodadvances.2024013073.
3
Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia.
多中心随机对照试验方案,旨在研究暂时暂停布鲁顿酪氨酸激酶抑制剂治疗以与 SARS-CoV-2 疫苗接种同步进行及其对慢性淋巴细胞白血病患者免疫反应的影响。
BMJ Open. 2023 Sep 28;13(9):e077946. doi: 10.1136/bmjopen-2023-077946.
4
Infections in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者的感染
Hematol Transfus Cell Ther. 2023 Jul-Sep;45(3):387-393. doi: 10.1016/j.htct.2023.05.006. Epub 2023 Jul 1.
5
Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者 COVID-19 疫苗失败的原因和后果。
Eur J Haematol. 2022 Feb;108(2):91-98. doi: 10.1111/ejh.13722. Epub 2021 Dec 5.
6
Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?免疫能力能否在慢性淋巴细胞白血病中恢复?
Hematol Oncol Clin North Am. 2021 Aug;35(4):827-845. doi: 10.1016/j.hoc.2021.03.010. Epub 2021 May 26.
7
Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review.慢性淋巴细胞白血病诱导的体液免疫抑制:系统评价。
Cells. 2020 Nov 2;9(11):2398. doi: 10.3390/cells9112398.
8
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.3 项关键性研究中单药伊布替尼治疗慢性淋巴细胞白血病患者的长期安全性。
Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761.
9
A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia.从加拿大视角看免疫球蛋白疗法在降低慢性淋巴细胞白血病感染并发症方面的应用
Curr Oncol. 2016 Feb;23(1):42-51. doi: 10.3747/co.23.2810. Epub 2016 Feb 18.
10
The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells.BAFF受体TACI通过调节性B细胞和慢性淋巴细胞白血病B细胞控制白细胞介素-10的产生。
Leukemia. 2016 Jan;30(1):163-72. doi: 10.1038/leu.2015.174. Epub 2015 Jul 3.